US EditionCombination Therapies: Satellos CSO on Future of Treatment – Archyde
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Combination Therapies: Satellos CSO on Future of Treatment – Archyde
Archyde The Future of Duchenne Muscular Dystrophy Treatment: Why Combination Therapies Are Likely the Key Imagine a future where a diagnosis of Duchenne muscular dystrophy (DMD) doesn’t automatically equate to a rapidly declining quality of life. While currently a devastating genetic disorder, recent advancements, particularly with Satellos Bioscience’s SAT-3247, are hinting at a paradigm shift – ... Read more You can read the full story here: C…
Combination Therapies Could Be a 'Fantastic Way Forward for Patients," Says Satellos Chief Scientific Officer
Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific officer says the complexity of Duchenne muscular dystrophy may ultimately mean that a number of different therapies will be used together,
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
